The week that was Week ending July 8
I must admit to feeling somewhat frustrated. Having corresponded with the Hot Copper forum on three occasions now with no response I have reached the conclusion the customer service arm of the site is akin to the bots wreaking havoc with the IMU share price in recent years, either computer generated or simply out to lunch. Either way my recent posts have vanished and it is time to move on.
Last week in expert talks with Kalkine Media Imugene MD & CEO focused on some points which hint at an even stronger valuation for Her Vaxx than those outlined by myself in recent weeks. Put simply Chong notes the Phase 2 trial was conducted not only on late stage patients, but at the lower rate of 50mg per dose. Now with the ability and regulatory approval to administer the higher dose rate of 100mg per patient, she clearly envisages Her Vaxx results being much better in future trials, than those realised thus far. This acknowledgement is astounding considering some patients treated with Her Vaxx at the lower dose rate of 50mg are still alive after 900 days of being treated. Firing up earlier stage patients immunity with the higher dose could potentially extend life further than the 5.9 months exhibited beyond the existing standard of care in the recent phase 2 OSR trial results. Not to mention all this taking place in an environment where Her Vaxx patients experience less toxicity and side effects than they do on alernate treatment arms. How does one place a valuation on these outcomes? Either as a stand alone vaccine or in combination with leading Big Pharma drugs Her Vaxx represents significant value to Imugene’s bottom line. 5 times peak annual sales is the figure many in the industry turn to when assessing successful product valuations, and Her Vaxx must now be considered worthy of that that stable. On any calculation Her Vaxx adds much more than a $1 to the existing IMU share price.
Speaking of dosage rates, in the aforementioned interview Leslie eludes to the fact initial findings from the CF33 Check Vacc trial are encouraging. This is music to the ears of many long term holder who recognise the opportunity Yuman Fong’s powerful oncolytic viruses’ offer both cancer patients and investors alike. Then Chong extends the blue sky even further in hinting investors shall be bouyed by information soon to be released surrounding the development of Imugenes Oncarlytics platform, in concert with Celularity and Eureka. With the potential to obliterate solid tumours in cancer patients, CF33, Vaxinia and CD19 could springboard the Imugene Oncarlytics platform into the stratosphere, if Saul Priceman, Yuman Fong and the team at City of Hope are on the money.
For me I was keen to hear last week Pravin Kaumaya of the Ohio State University is speaking as part of this years Immuno UK Series. Kaumaya is sure to speak about his Imugene licensed PD1 Vaxx in addition to his research into additional B-cell epitope vaccine inhibitors such as PD-L1, LAG-3, and TIM3. In previous posts I have outlined Kaumaya’s research noted online at https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1818437 wherein it is mentioned with respesct to his research “The greatest potential significance of our strategy is two-fold: (i) It combines multiple mechanisms of action by activating both B- and T-cell functions and promoting immunological clearance and (ii) It is a targeted approach aimed at inhibiting molecular signaling pathways that are crucial for tumor growth and maintenance. Active immunotherapy offers many advantages, including tumor specificity and the activation of immune responses against antigens that are selectively expressed by tumor cells. Additional benefits of the peptide vaccine approach include the ease and rapid synthesis, safety, lack of toxicity, and cost-effectiveness. Additional advantages of chimeric B- and T-cell vaccines are exquisite specificity and the potential for a durable treatment effect that can be recalled due to immunologic memory. Furthermore, combination anti-PD-1 immunization therapy with anti-HER-2 immunization therapy produced high immunogenicity and greater inhibition of tumor growth. The combined vaccines were safe with no evidence of toxicity or autoimmunity. The development of a PD-1 vaccine in this proposal is highly innovative and when combined with an HER-2 vaccine represents a highly novel promising effective candidate for the treatment of several different metastatic cancers including, colon, breast, and lung.
As Kaumaya himself canvassed in the recent Imugene Science series 2 PD1 therapy in combination with HER 2 immunization therapy is poised for many more breakthroughs and significant new improvements in the treatment of patients with cancers for maximum clinical benefits. I for one eagerly await his presentation and with it a more detailed update pertaining to the success of Imugene’s PD1 Vaxx trial on humans at the Cabrini Hospital in Melbourne. This could be a gamne changer for cancer patients worldwide.
The share price and the week that was
Whilst leading brokers Goldman Sachs and JP Morgan have been busying themselves buying IMU shares in recent months, the local market appears to be languishing. As an example the paid recipients of IMU fundraising efforts, Bell Potter, are dawdling toward the bottom of the table in the IMU order of merit, when it comes to net inflows and outflows of IMU stock bought and sold. Clearly sophisticated investors and fund managers are taking over the share register from nervous Mums, Dads and individuals, who traditionally head for the dressing sheds when the tide turns out. Or at worst the bathroom depending on their nerves. A middle page spread in the AFR or Australian on exactly what Imugene has to offer the cancer treatment world or for that matter Australia, would assist the cause, but that’s not likely to occur this week. Keep in mind whilst you and I are aware of Imugene and their immense value proposition, most Australians wouldn’t know of or have even heard of Imugene. A Channel 7 News Report on CF33 some time ago was a fleeting eye opener to families on Struggle Street, but not enough to ignite a flame. No, it’s now all up to the science and pending announcements when it comes to stock volumes. The market cannot rely on social media, hype and influencers to drive traffic IMU’s way. Gamestop and Tesla the stock is not.
That said the bulls are slowly defeating the bears in the tug of war taking place within the share price at present. The Her Vaxx results reaffirmed Imugene’s B cell platform, whilst news CF33 is playing the game has undoubtedly lifted all boats. But where to now?
This week the macroeconomic equation appeared to be stabilising. Despite better than expected jobs data out of the US last night there are signs rising interest rates are subduing if not quelling demand. Supply chain issues are sure to exacerbate inflationary pressures in the near term, as are the geopolitical tensions in Europe, yet Central Banks around the world are slowly delivering monetary policy to wind back years of much needed stimulus, and suppress both demand and inflation levels in the process. This could play into IMU’s hands as the stock is perceived to be at the growth end of the scale in equity portfolio weightings. Another factor which is soon to increase share volumes is the plethora of trial indications and results coming IMU’s way. Good news and company announcements could potentially close out many of the 300 million plus shares currently shorted on the register, adding further impetus to an already rising IMU chart. It would appear the recent rise above historic IMU Moving Day Averages may not be short lived.
But enough of cancer research, macroeconomicsa and stock prices. From droughts, bushfires, epidemics, wars and floods the world has gone literally mad of late. With this in mind I thought I’s take this opportunity to close out the weekend with no, not politics, but with some poetry. This poem I penned during the week is about a cattleman who inadvertenly finds the second love of his life, albeit in midst of a drought. With the news around IMU being all good at present I though I’d afford the poem the title “The ride home”.
Given IMU’s affiliation with cattlemen I hope you enjoy the thread…
Have a good week and enjoy the sunshine while it lasts..Best of luck to all LTH’s.
The ride home
Dust left his fingerprints
finding its way further into the bridles leather
A burnt out gums fallen branch spooking his bay mare
as he angled southwards
The dogs were further ahead
Barking aimlessly at two bullocks in the timber beyond
his stirrup iron clashing against the rock cliffs face
In the hill country he felt at home
alone
Within himself
Riding toward the stream
he now disembarked
Crevicing the palm of his hands
to scoop water to his lips
As two dogs approached
at an eager rapid clip
T’was but mid morning
though he was grateful for a sip
For already under his Akubra
his brow was cusped in sweat
The chase had been long
and one with much regret
Now he would leave the bullocks
in the high country to their lot
For another day he thought
with a better thought out plot
The ride home was restless
failure on his mind
The heat relentless
clinging to his spine
As flies soon encircled him
preying on the mare
Clutching to her mane
oblivious to his stare
Or was it now his glare
frustrated and intense
Catching sight of his wife
as she tended to their fence
Before gathering in his bridle
her hands too covered in dust
Reaching for his wrist
grateful for his touch
They’re still out there he said
waiting for her reply
Yet all she did was smile
catching his solemn eye
Then Cheer up cowboy she whispered
before letting the bridle free
Things could be worse, she said
You may never have met me
In the grips of despair
the sentence of their drought
Wandering aimlessly toward the shed
he brushed the cobwebs out
Away from his late fathers desk
to unlock the bottom drawer
His mind now recalling
the words his father swore
Don’t visit here unless you need to
he could here his father say
This isn’t one for trading
or for that matter a short term play
Hold onto it for her
if you plan on her staying
One day you may children
and for that I’m simply saying
Hold this scrip tightly
never let it go
There’s gold here in these letters
though I realise there’s but three
Behind each is a meaning
transcending you and me
It’s a story about cancer
but that’s for another day
My son they have the answer
so sit on them and stay
For without this in your hands
you may well run astray
Then opening up the envelope
to grasp the ageing scrip
Large figures stared him down
as the midday sun shone through
Three letters appeared before him
The scrip read IMU
Then a voice did softly whisper
As he set the dusty scrip free
Cheer up cowboy it said
In time you shall see
Things could have be worse
You may have never met me…
WMHB
(20min delay)